Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Osteoporosis | Current Treatment | US | 2016

Login to access report north_east
Contact sales account_box

The treatment of osteoporosis represents a large market that is dominated by the bisphosphonate drug class. Although more-efficacious therapies are available, step therapy is commonplace, with these therapies usually relegated to later lines because of their higher prices, duration restrictions, and/or injectable mode of delivery. Additionally, osteoporosis diagnosis and compliance rates are low mainly because of patients’ concern about rare but serious side effects of medications, the asymptomatic nature of the disease, and a limited understanding of the seriousness of osteoporosis. However, despite these obstacles, select branded therapies have achieved significant sales. Opportunities exist for emerging agents in osteoporosis, but these agents will likely face challenges.

QUESTIONS ANSWERED

  • What is the current patient share of branded therapies such as Eli Lilly’s Forteo and Amgen’s Prolia?
  • What effect has the launch of Radius Health’s Tymlos had on treatment decisions?
  • What are the anticipated changes in prescribing patterns over the next 12 months?
  • What effect do physicians think the launch of Amgen / UCB’s Evenity would have? Which patients would most likely be prescribed Evenity? Which current therapies would be most affected by Evenity’s launch?
  • What are U.S. specialists’ attitudes and perceptions regarding diagnosis and treatment of osteoporosis?
  • What are the drivers and constraints determining prescribing practices for osteoporosis?

Scope

  • Geography: United States.
  • Primary Research: Survey of 100 U.S. rheumatologists / endocrinologists / PCPs.
  • Key Drugs Covered: Prolia, Tymlos, Forteo, oral and IV bisphosphonates, SERMs, HRT, calcitonin.
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Current Treatment: Physician Insights – Major Depressive Disorder (EU5)
Across the EU5, the treatment landscape for major depressive disorder (MDD) is shaped by the widespread use of SSRIs and SNRIs, which continue to serve as firstline therapy due to their…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east